Experienced in Ovarian Carcinosarcoma

Dr. Delphine W. Ong

Oncology
3301 C Street, Building 500, 
Sacramento, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Ovarian Carcinosarcoma
3301 C Street, Building 500, 
Sacramento, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Delphine Ong is an Oncologist in Sacramento, California. Dr. Ong is rated as an Experienced provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Inflammatory Breast Cancer, and Classical Hodgkin Lymphoma.

Her clinical research consists of participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

3301 C Street, Building 500, Sacramento, CA 95816

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
View 4 Less Clinical Trials
Similar Doctors
Distinguished in Ovarian Carcinosarcoma
Dr. Babak Edraki
Obstetrics and Gynecology | Oncology | Gynecologic Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Babak Edraki
Obstetrics and Gynecology | Oncology | Gynecologic Oncology

John Muir Physician Network

177 La Casa Via, Suite 200e, 
Walnut Creek, CA 
 (56.1 miles away)
925-692-5927
Languages Spoken:
English, Farsi, French
See accepted insurances
Offers Telehealth

Babak Edraki is an Obstetrics and Gynecologist and an Oncologist in Walnut Creek, California. Dr. Edraki is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Endometrial Cancer, Ovarian Carcinosarcoma, Endometrial Stromal Sarcoma, Hernia Surgery, and Ureteral Reconstruction.

Distinguished in Ovarian Carcinosarcoma
Dr. Wiley L. Fowler
Gynecologic Oncology | Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Wiley L. Fowler
Gynecologic Oncology | Oncology

Dignity Health Medical Foundation

3301 C St, Suite 550, 
Sacramento, CA 
 (0.1 miles away)
916-733-5300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Wiley Fowler is a Gynecologic Oncologist and an Oncologist in Sacramento, California. Dr. Fowler is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Testicular Yolk Sac Tumor, Oophorectomy, and Hernia Surgery.

Distinguished in Ovarian Carcinosarcoma
Dr. Rachel Ruskin
Gynecologic Oncology | Oncology | Palliative Medicine
Distinguished in Ovarian Carcinosarcoma
Dr. Rachel Ruskin
Gynecologic Oncology | Oncology | Palliative Medicine

Physician Assistant Surgical Assist Inc

2825 Capitol Ave, 
Sacramento, CA 
 (1.1 miles away)
916-887-0000
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Rachel Ruskin is a Gynecologic Oncologist and an Oncologist in Sacramento, California. Dr. Ruskin has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ovarian Cancer, and Oophorectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ong's expertise for a condition
ConditionClose
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile